At-Risk Launches: Neurontin Settlement Leaves Question Of Jury Damage Calculations Unresolved
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva and Actavis settle with Pfizer two weeks into a jury trial to determine liability and damages for launching generic gabapentin at-risk.